Von Willebrand Factor and Protein C Ratio in Graft Function After Liver Transplant
- Conditions
- Liver Transplant; Complications
- Registration Number
- NCT04324255
- Lead Sponsor
- Asan Medical Center
- Brief Summary
In liver cirrhosis (LC),the activity of von Willebrand factor (vWF)-cleaving enzyme ADAMTS13 is reduced in LC patients and consequent progression of liver injury. Remarkably, it has been reported that a severe vWF/ADAMTS13 imbalance develops during liver transplantation (LT) and persists even after LT. Such changes are thought to contribute to postoperative thrombotic complications, which may lead to early adverse events of thrombotic microangiopathy after living-donor LT (LDLT). We investigated whether vWFPCR could predict EAD or graft failure following LT and compared it with FVIIIPCR, procoagulant, such as vWF and FVIII and anticoagulant, such as PC.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1199
patients who underwent LT
deceased-donor liver transplant, and insufficient data, ABO-incompatible LT
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Early allograft dysfunction within 7 days after surgery Immediate liver graft function
- Secondary Outcome Measures
Name Time Method Graft failure 90 days re-liver transplantation or death, whichever was first
intensive care unit stay until the day of patients moving to general wards, through study completion, an average of 1 year days of intensive care unit stay after liver transplant
Trial Locations
- Locations (1)
Asan Medical center
🇰🇷Seoul, Korea, Republic of
Asan Medical center🇰🇷Seoul, Korea, Republic of